Antiplatelet therapies bring an increased risk of bleeding, especially in the elderly.. Antithrombotic therapy increases bleeding risk in CAD patients: Research Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and persistent coronary artery disease , yet it is associated with an elevated risk of bleeding also. Professor Freek Verheugt led the research. This data, however, ought to be treated with caution because it comes from post-hoc evaluation of randomised control trials. Related StoriesNew Haven Pharmaceuticals' DURLAZA medication delivers sustained antiplatelet control for complete 24 hoursCHOP's Buerger Center for Advanced Pediatric Care celebrates grand openingFirst medical center installs Ortho Vision AnalyzerThe TRITON and PLATO clinical trials demonstrated that newer ADP blockers such as for example prasugrel and ticagrelor are far better that clopidogrel.Joon-Il Jun, a postdoctoral fellow working in Lau’s lab and first author of the paper, discovered that fibroblasts recruited to the site of pores and skin wounds were entering circumstances of reproductive dormancy, or cell-cycle arrest, known as senescence. This was quite unexpected, Jun said. Until now senescence was thought to happen in cells that experienced DNA damage – – to prevent them from proliferating and, possibly, becoming cancerous. Related StoriesSAGE partners with The Katie Piper Base to launch journal Marks, Burns & HealingAllergan receives FDA authorization to advertise 28 additional varieties of Natrelle 410 silicone-filled breast implantsMesenchymal stem cell exosomes offer hope in healing chronic woundsHe discovered that the senescent fibroblasts had been producing proteins that degraded the extracellular matrix and accelerated the breakdown of collagen.